Suppr超能文献

宏基因组学下一代测序在先天性心脏病手术后呼吸道病毒感染诊断中的应用价值

Application value of metagenomics next-generation sequencing in the diagnosis of respiratory virus infection after congenital heart surgery.

作者信息

Chen Xiu-Hua, Zhou Si-Jia, Liu Ying-Ying, Cao Hua, Zheng Yi-Rong, Chen Qiang

机构信息

Department of Cardiac Surgery, Fujian Children's Hospital (Fujian Branch of Shanghai Children's Medical Center), College of Clinical Medicine for Obstetrics & Gynecology and Pediatrics, Fujian Medical University, Fuzhou, China.

出版信息

Transl Pediatr. 2024 Feb 29;13(2):260-270. doi: 10.21037/tp-23-341. Epub 2024 Feb 26.

Abstract

BACKGROUND

Timely and accurate pathogen diagnosis can be challenging in children who contract a respiratory virus following congenital heart surgery (CHS). This often results in suboptimal drug use and treatment delays. Metagenomics next-generation sequencing (mNGS) is a swift, efficient, and unbiased method for obtaining microbial nucleic acid sequences. This technology holds promise as a comprehensive diagnostic tool, especially for pathogens undetectable by traditional methods. However, the efficacy of mNGS in the context of congenital heart disease infections remains uncertain. This study aimed to explore the diagnostic value of mNGS for respiratory virus infections post-CHS.

METHODS

We conducted a retrospective analysis of patients who developed respiratory tract infections post-CHS and were admitted to our cardiac center between July 2021 and December 2022. The patients were categorized into the following two groups based on the diagnostic method used: (I) the mNGS group (comprising 62 patients); and (II) the conventional microbiological test (CMT) group (comprising 70 patients). Bronchoalveolar lavage fluid (BALF) samples from these patients were tested to identify pathogens.

RESULTS

The mNGS group had significantly higher detection rates for both viral infections and mixed viral infections than the CMT group (56.45% . 17.14%, P<0.001, and 80.00% . 16.67%, P<0.001, respectively). In the mNGS group, 19.35% of the patients received antiviral therapy, and 61.29% received an anti-infective regimen adjustment. Conversely, in the CMT group, only 4.29% received antiviral therapy, and 28.57% received an anti-infective regimen adjustment. A higher percentage of patients showed improved respiratory symptoms in the mNGS group than the CMT group (74.19% . 44.29%, P=0.001). Additionally, the mNGS group had a shorter duration of mechanical ventilation and a reduced length of stay in the cardiac intensive care unit than the CMT group (P=0.012).

CONCLUSIONS

Using mNGS for BALF enhances the detection of respiratory viral infections and coexisting viral infections post-CHS. This facilitates more precise treatment strategies and could potentially lead to improved patient outcomes.

摘要

背景

对于先天性心脏病手术后(CHS)感染呼吸道病毒的儿童,及时准确的病原体诊断可能具有挑战性。这通常会导致药物使用不当和治疗延迟。宏基因组学下一代测序(mNGS)是一种快速、高效且无偏见的获取微生物核酸序列的方法。这项技术有望成为一种全面的诊断工具,特别是对于传统方法无法检测到的病原体。然而,mNGS在先天性心脏病感染中的疗效仍不确定。本研究旨在探讨mNGS对CHS后呼吸道病毒感染的诊断价值。

方法

我们对2021年7月至2022年12月期间在我们心脏中心住院的CHS后发生呼吸道感染的患者进行了回顾性分析。根据使用的诊断方法,将患者分为以下两组:(I)mNGS组(62例患者);(II)传统微生物检测(CMT)组(70例患者)。对这些患者的支气管肺泡灌洗(BALF)样本进行检测以鉴定病原体。

结果

mNGS组的病毒感染和混合病毒感染检测率均显著高于CMT组(分别为56.45%对17.14%,P<0.001,以及80.00%对16.67%,P<0.001)。在mNGS组中,19.35%的患者接受了抗病毒治疗,61.29%的患者接受了抗感染方案调整。相反,在CMT组中,只有4.29%的患者接受了抗病毒治疗,28.57%的患者接受了抗感染方案调整。mNGS组中表现出呼吸道症状改善的患者比例高于CMT组(74.19%对44.29%,P=0.001)。此外,mNGS组的机械通气时间和在心脏重症监护病房的住院时间均短于CMT组(P=0.012)。

结论

使用mNGS检测BALF可提高CHS后呼吸道病毒感染和并存病毒感染的检测率。这有助于制定更精确的治疗策略,并可能改善患者预后。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd9c/10915445/dc11afc7c86e/tp-13-02-260-f1.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验